Successful treatment with secukinumab in a 4-month-old infant with severe generalized pustular psoriasis: a case report.

INTRODUCTION

Secukinumab has demonstrated favorable efficacy and safety in the management of plaque psoriasis; however, its use in generalized pustular psoriasis (GPP) remains limited, particularly in children under 6 years of age, with only a few clinical reports available.

CASE DESCRIPTION: A 4-month-old infant was admitted with a 2-month history of GPP, which had worsened over the previous week with extensive erythematous rashes and pruritus. More than 70% of the body surface area was affected, with progression toward erythroderma. The Japanese Dermatological Association Severity Index score was 7, indicating moderate severity. Treatment with secukinumab 50 mg weekly, combined with daily emollients, was initiated. Complete clearance of skin lesions was achieved after four injections. One year after discontinuation of secukinumab, recurrence occurred; a single re-administration of secukinumab resulted in near-complete resolution.

CONCLUSION

Secukinumab may provide potential clinical benefits with an acceptable safety profile in infants with GPP. Further research is required to establish the optimal treatment duration, dosing intervals, and long-term safety in this population.